Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Predesigned Synthetic sgRNAs

Horizon Discovery is now offering predesigned synthetic single guide RNA (sgRNA). The sgRNAs are available individually or as library collections, and are being offered as an expansion to the company's Edit-R gene engineering platform. Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts, even in complex, difficult-to-edit cell types and experimental models, Horizon said. The synthetic sgRNAs have been designed to maximize the likelihood of functionally knocking out the gene or genes of interest while minimizing off-target effects.

When paired with Cas9 mRNA or Cas9 protein, the sgRNAs also allow researchers to perform DNA-free gene editing in a new one-part format, streamlining their gene editing workflows without the potential for nuclease or guide integration into the cell's genome. They can also be paired with expressed formats such as Cas9 integrated cell lines.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.